Overview

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Status:
Active, not recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a phase Ⅲ, randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the efficacy, safety, tolerability, and immunogenicity of subcutaneous Tildrakizumab in subjects with moderate to severe chronic plaque psoriasis. The trial was divided into two parts: the base study (Week 0- Week 12) and the extension study (Week 13- Week 54).
Phase:
Phase 3
Details
Lead Sponsor:
Shenzhen Kangzhe Pharmaceutical Co., Ltd.